SpiceJet, PLUSS Come together for safe vaccine delivery, sign MoU

To maintain it potency, SpiceJet will transport vaccines in PLUSS's indigenously developed temperature control boxes.

SpiceJet, PLUSS Come together for safe vaccine delivery, sign MoU

THD NewsDesk, New Delhi. Domestic commercial Airlines giant SpiceJet has recently signed a Memorandum of Understanding with Pluss Advanced Technologies (PLUSS) for supplying special temperature control boxes. These indigenously developed, precise devices help towards maintaining the potency and effectiveness of the Covid vaccine during aereal transportation.

The Memorandum states that PLUSS will supply Celsure, developed using proprietary Phase Change Material technology, for the smooth transportation of the vaccines, straight from the manufacturer to various parts of the country. The product is to be explicitly co-branded for Spice Xpress, SpiceJet’s cargo division, and made available at different locations across the country.

Samit Jain, MD, PLUSS, quoted “At PLUSS, we have been continuously working towards playing our role in getting India ready to effectively combat the COVID-19 pandemic, once the vaccine is approved for use. We are particularly happy to join forces with SpiceJet to ensure the delivery of the vaccine using the safest and fastest mode. SpiceJet flies to many non-metro locations and that will help the vaccine reach to the rural hinterlands of India.” 

Meanwhile, Sanjiv Gupta, CEO, SpiceJet Cargo, said, “Pluss has been a pioneer in Phase Change Material based temperature control solutions in India and will be the appropriate partner as we plan on moving the temperature-sensitive COVID-19 vaccines across the country. Spice Xpress has the biggest cargo fleet with more than 17 flights. We can cover the length and breadth of the country through our partnerships with last-mile logistics companies. We can deliver the vaccines within 48-72 hours to any part of the country, and Pluss’ temperature control boxes will play a critical role in ensuring the safety and efficacy of the vaccine.” 

 

Source: Express Pharma
Exit mobile version